ADMA Biologics Inc $ADMA Shares Bought by B Group Inc.

B Group Inc. grew its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 4.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,412,542 shares of the biotechnology company’s stock after purchasing an additional 95,000 shares during the quarter. ADMA Biologics makes up approximately 26.9% of B Group Inc.’s holdings, making the stock its biggest holding. B Group Inc. owned about 1.01% of ADMA Biologics worth $35,368,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Marathon Capital Management increased its holdings in ADMA Biologics by 64.5% in the third quarter. Marathon Capital Management now owns 466,570 shares of the biotechnology company’s stock valued at $6,840,000 after buying an additional 182,880 shares during the last quarter. iSAM Funds UK Ltd bought a new position in ADMA Biologics during the 3rd quarter worth approximately $34,000. Comerica Bank grew its position in shares of ADMA Biologics by 821.9% in the 3rd quarter. Comerica Bank now owns 772,634 shares of the biotechnology company’s stock worth $11,327,000 after acquiring an additional 688,828 shares in the last quarter. Jump Financial LLC bought a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $5,275,000. Finally, Landscape Capital Management L.L.C. bought a new position in ADMA Biologics during the third quarter worth $1,324,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $15.15 on Friday. ADMA Biologics Inc has a twelve month low of $13.76 and a twelve month high of $25.67. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. The firm has a 50-day moving average of $16.63 and a two-hundred day moving average of $16.71. The company has a market capitalization of $3.61 billion, a price-to-earnings ratio of 25.25 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting analysts’ consensus estimates of $0.20. The business had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The business’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.46 EPS. As a group, analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and a consensus target price of $32.00.

Insider Buying and Selling at ADMA Biologics

In related news, Director Steve Elms acquired 7,000 shares of ADMA Biologics stock in a transaction dated Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, with a total value of $109,690.00. Following the purchase, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. The trade was a 0.34% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.50% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.